Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

Oncology Letters

Volumn 5, Issue 1, 2012, Pages 201-207

  Lu, Qiang ^a   Lv, Gang ^a   Kim, Andre ^b   Ha, Jong Myung ^b   Kim, Suhkman ^c  

^a CHINA MEDICAL UNIVERSITY   (China)

^b Silla University   (South Korea)

^c Pusan National University   (South Korea)

Author keywords

Extracellular matrix metalloproteinase inducer; Osteosarcoma; Overall survival; Prognosis

Indexed keywords

CD147 ANTIGEN; CISPLATIN; DOXORUBICIN; METHOTREXATE;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CANCER ADJUVANT THERAPY; CANCER DIAGNOSIS; CANCER PROGNOSIS; CANCER SURGERY; CANCER SURVIVAL; CELL MEMBRANE; CONTROLLED STUDY; CYTOPLASM; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTIPLE CYCLE TREATMENT; OSTEOBLAST; OSTEOSARCOMA; OVERALL SURVIVAL; RETROSPECTIVE STUDY; WESTERN BLOTTING;

EID: 84869042291     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2012.981     Document Type: Article

References (40)

1. Clark JC, Dass CR and Choong PF: A review of clinical and molecular prognostic factors in osteosarcoma. J Cancer Res Clin Oncol 134: 281-297, 2008.
2. Davicioni E, Wai DH and Anderson MJ: Diagnostic and prognostic sarcoma signatures. Mol Diagn Ther 12: 359-374, 2008.
3. Fagioli F, Biasin E, Mereuta OM, et al: Poor prognosis osteosarcoma: new therapeutic approach. Bone Marrow Transplant 41 (Suppl2): S131-S134, 2008.
4. Sakamoto A and Iwamoto Y: Current status and perspectives regarding the treatment of osteo-sarcoma: chemotherapy. Rev Recent Clin Trials 3: 228-231, 2008.
5. Wang LL: Biology of osteogenic sarcoma. Cancer J 11: 294-305, 2005.
6. Federman N, Bernthal N, Eilber FC and Tap WD: The multidisciplinary management of osteosarcoma. Curr Treat Options Oncol 10: 82-93, 2009.
7. Hakuma N, Betsuyaku T, Kinoshita I, et al: High incidence of extracellular matrix metalloproteinase inducer expression in non-small cell lung cancers. Association with clinicopathological parameters. Oncology 72: 197-204, 2007.
8. Jia L, Wei W, Cao J, Xu H, Miao X and Zhang J: Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells. Ann Hematol 88: 753-760, 2009.
9. Aratake Y, Marutsuka K, Kiyoyama K, et al: EMMPRIN (CD147) expression and differentiation of papillary thyroid carcinoma: implications for immunocytochemistry in FNA cytology. Cytopathology 21: 103-110, 2009.
10. Chen T and Zhu J: Evaluation of EMMPRIN and MMP-2 in the prognosis of primary cutaneous malignant melanoma. Med Oncol 27: 1185-1191, 2009.
11. Zhang C, Tu Z, Du S, Wang Y and Wang Q: Expression of matrix metalloproteinase 2 and extracellular matrix metalloproteinase inducer are unfavorable postoperative prognostic factors in intrahepatic cholangiocarcinoma. Pathol Oncol Res 16: 47-53, 2010.
12. Buergy D, Fuchs T, Kambakamba P, et al: Prognostic impact of extracellular matrix metalloprotease inducer: immunohistochemical analyses of colorectal tumors and immunocytochemical screening of disseminated tumor cells in bone marrow from patients with gastrointestinal cancer. Cancer 115: 4667-4678, 2009.
13. Liang YX, He HC, Han ZD, et al: CD147 and VEGF expression in advanced renal cell carcinoma and their prognostic value. Cancer Invest 27: 788-793, 2009.
14. Han ZD, Bi XC, Qin WJ, et al: CD147 expression indicates unfavourable prognosis in prostate cancer. Pathol Oncol Res 15: 369-374, 2009.
15. Ju XZ, Yang JM, Zhou XY, Li ZT and Wu XH: EMMPRIN expression as a prognostic factor in radiotherapy of cervical cancer. Clin Cancer Res 14: 494-501, 2008.
16. Sillanpaa S, Anttila M, Suhonen K, et al: Prognostic significance of extracellular matrix metalloproteinase inducer and matrix metalloproteinase 2 in epithelial ovarian cancer. Tumour Biol 28: 280-289, 2007.
17. Yang JM, O'Neill P, Jin W, et al: Extracellular matrix metalloproteinase inducer (CD147) confers resistance of breast cancer cells to anoikis through inhibition of Bim. J Biol Chem 281: 9719-9727, 2006.
18. Zhu H, Evans B, O'Neill P, et al: A role for p53 in the regulation of extracellular matrix metalloproteinase inducer in human cancer cells. Cancer Biol Ther 8: 1722-1728, 2009.
19. Bougatef F, Quemener C, Kellouche S, et al: EMMPRIN promotes angiogenesis through hypoxia-inducible factor-2alpha-mediated regulation of soluble VEGF isoforms and their receptor VEGFR-2. Blood 114: 5547-5556, 2009.
20. Tang Y, Nakada MT, Kesavan P, et al: Extracellular matrix metalloproteinase inducer stimulates tumor angiogenesis by elevating vascular endothelial cell growth factor and matrix metalloproteinases. Cancer Res 65: 3193-3199, 2005.
21. Zheng HC, Takahashi H, Murai Y, et al: Upregulated EMMPRIN/CD147 might contribute to growth and angiogenesis of gastric carcinoma: a good marker for local invasion and prognosis. Br J Cancer 95: 1371-1378, 2006.
22. Duivenvoorden WC, Hirte HW and Singh G: Transforming growth factor beta1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells. Clin Exp Metastasis 17: 27-34, 1999.
23. Quemener C, Gabison EE, Naimi B, et al: Extracellular matrix metalloproteinase inducer up-regulates the urokinase-type plasminogen activator system promoting tumor cell invasion. Cancer Res 67: 9-15, 2007.
24. Riethdorf S, Reimers N, Assmann V, et al: High incidence of EMMPRIN expression in human tumors. Int J Cancer 119: 1800-1810, 2006.
25. Wang P, Xu TY, Guan YF, Su DF, Fan GR and Miao CY: Perivascular adipose tissue-derived visfatin is a vascular smooth muscle cell growth factor: role of nicotinamide mononucleotide. Cardiovasc Res 81: 370-380, 2009.
26. Wang P, Xu TY, Guan YF, et al: Nicotinamide phosphoribosyltransferase protects against ischemic stroke through SIRT1-dependent adenosine monophosphate-activated kinase pathway. Ann Neurol 69: 360-374, 2011.
27. Wang P, Guan YF, Du H, Zhai QW, Su DF and Miao CY: Induction of autophagy contributes to the neuroprotection of nicotinamide phosphoribosyltransferase in cerebral ischemia. Autophagy 8: 77-87, 2012.
28. Wang P, Zhang RY, Song J, et al: Loss of AMP-activated protein kinase-alpha2 impairs the insulin-sensitizing effect of calorie restriction in skeletal muscle. Diabetes 61: 1051-1061, 2012.
29. Enneking WF, Spanier SS and Goodman MA: A system for the surgical staging of musculoskeletal sarcoma. Clin Orthop Relat Res 153: 106-120, 1980.
30. Enneking WF, Spanier SS and Goodman MA: Current concepts review. The surgical staging of musculoskeletal sarcoma. J Bone Joint Surg Am 62: 1027-1030, 1980.
31. Picci P, Bacci G, Campanacci M, et al: Histologic evaluation of necrosis in osteosarcoma induced by chemotherapy. Regional mapping of viable and nonviable tumor. Cancer 56: 1515-1521, 1985.
32. Wang P, Yang FJ, Du H, et al: Involvement of leptin receptor long isoform (LepRb)-STAT3 signaling pathway in brain fat mass-and obesity-associated (FTO) downregulation during energy restriction. Mol Med 17: 523-532, 2011.
33. Zhou Q, Zhu Y, Deng Z, Long H, Zhang S and Chen X: VEGF and EMMPRIN expression correlates with survival of patients with osteosarcoma. Surg Oncol 20: 13-19, 2011.
34. Madigan MC, Kingsley EA, Cozzi PJ, Delprado WJ, Russell PJ and Li Y: The role of extracellular matrix metalloproteinase inducer protein in prostate cancer progression. Cancer Immunol Immunother 57: 1367-1379, 2008.
35. Ishibashi Y, Matsumoto T, Niwa M, et al: CD147 and matrix metalloproteinase-2 protein expression as significant prognostic factors in esophageal squamous cell carcinoma. Cancer 101: 1994-2000, 2004.
36. Nabeshima K, Iwasaki H, Koga K, Hojo H, Suzumiya J and Kikuchi M: Emmprin (basigin/CD147): matrix metalloproteinase modulator and multifunctional cell recognition molecule that plays a critical role in cancer progression. Pathol Int 56: 359-367, 2006.
37. Cheng MF, Tzao C, Tsai WC, et al: Expression of EMMPRIN and matriptase in esophageal squamous cell carcinoma: correlation with clinicopathological parameters. Dis Esophagus 19: 482-486, 2006.
38. Dean NR, Newman JR, Helman EE, et al: Anti-EMMPRIN monoclonal antibody as a novel agent for therapy of head and neck cancer. Clin Cancer Res 15: 4058-4065, 2009.
39. Kuang YH, Chen X, Su J, et al: RNA interference targeting the CD147 induces apoptosis of multi-drug resistant cancer cells related to XIAP depletion. Cancer Lett 276: 189-195, 2009.
40. Han ZD, He HC, Bi XC, et al: Expression and clinical significance of CD147 in genitourinary carcinomas. J Surg Res 160: 260-267, 2010.